OrbiMed’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

OrbiMed’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-62,121	Closed	-$250K	–	141
2023 Q3	$250K	Sell	62,121 -1	-0%	-$7	0.01%	126
2023 Q2	$441K	Hold	62,122	–	–	0.01%	124
2023 Q1	$462K	Sell	62,122 -89,528	-59%	-$753K	0.01%	121
2022 Q4	$1.1M	Sell	151,650 -150,941	-50%	-$1.27M	0.02%	108
2022 Q3	$2.94K	Sell	302,591 -1,360	-0.4%	-$25.4K	0.05%	116
2022 Q2	$5.8K	Hold	303,951	–	–	0.11%	108
2022 Q1	$15.1M	Buy	303,951 +13,600	+5%	+$705K	0.24%	79
2021 Q4	$21.9M	Buy	290,351 +29,220	+11%	+$1.99M	0.28%	82
2021 Q3	$20.6M	Hold	261,131	–	–	0.23%	95
2021 Q2	$36.2M	Buy	261,131 +32,561	+14%	+$6.21M	0.37%	72
2021 Q1	$47.8M	Buy	228,570 +45,000	+25%	+$9.02M	0.45%	63
2020 Q4	$30.5M	Hold	183,570	–	–	0.27%	83
2020 Q3	$31.2M	Hold	183,570	–	–	0.39%	69
2020 Q2	$30.5M	Sell	183,570 -61,071	-25%	-$9.53M	0.43%	64
2020 Q1	$28.3M	Hold	244,641	–	–	0.48%	56
2019 Q4	$36.2M	Hold	244,641	–	–	0.52%	54
2019 Q3	$33.4M	Hold	244,641	–	–	0.63%	47
2019 Q2	$31.8M	Hold	244,641	–	–	0.49%	51
2019 Q1	$23.2M	Buy	+244,641	New	+$32.2M	0.36%	67

Other funds holding HARP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed's HARP Position: Q4 2023 in Review

OrbiMed sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2023, closing a stake of 62,121 shares — an estimated $250K sold.

OrbiMed first reported a position in HARP in Q1 2019 and held it in 19 quarters. The position peaked at $47.8M in Q1 2021. 41 funds tracked by Wall St. Rank hold HARP as of Q4 2023.

OrbiMed reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 62,121 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $250K.
OrbiMed first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 19 quarters.
OrbiMed's Harpoon Therapeutics, Inc. Common Stock position peaked at $47.8M in Q1 2021.
41 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.